Business Wire

YOKOGAWA/SENSIRE

6.6.2019 08:02:06 CEST | Business Wire | Press release

Share
Yokogawa Takes Strategic Stake in Finnish Company Sensire Ltd. to Pursue Collaboration in Cold Chain Monitoring

Yokogawa Electric Corporation (TOKYO:6841) and Finland-based Sensire Ltd. announce that they have reached an agreement for Yokogawa to take a €6 million stake in Sensire and to begin collaborating in the cold chain monitoring field. Through this initiative, both companies aim to develop and provide new services that combine Yokogawa’s Industrial Internet of Things (IIoT) architecture, subscription-based IIoT services being developed by its amnimo Inc. subsidiary, and Sensire’s cold chain temperature monitoring solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005285/en/

Demand for solutions that facilitate the temperature-controlled transportation of perishable items from the point of origin to the point of consumption is on the rise, and this need is particularly acute with pharmaceutical and food products that require strict temperature control.

Sensire Ltd. offers a full range of specialized temperature monitoring solutions mainly for the cold chain. Sensire’s compact and power efficient temperature sensors collect and transmit temperature data to the cloud for access from PCs and mobile devices. Supporting a range of wireless communication protocols suitable for land, sea, and air transport applications, Sensire’s solutions ensure access to continuous real-time monitoring data that delivers vital quality and compliance information when and where it is needed.

Yokogawa is developing a cloud-based IIoT architecture in collaboration with Microsoft Corporation of the United States, and based on this is starting to provide solutions for the remote monitoring of physical quantities. In addition, Yokogawa’s amnimo Inc. business unit is developing IIoT services that use this architecture to provide access to data from not only manufacturing plants but also many other types of facilities and situations, with the aim of delivering subscription-based Measurement as a Service (MaaS).

Having taken a 35.2% stake in Sensire, Yokogawa is now this company’s largest shareholder. Utilizing Yokogawa’s know-how and global network, the two companies will work together to develop new temperature monitoring solutions for the cold chain and other logistics services, and expand this business.

Tsuyoshi Abe, a Yokogawa senior vice president and head of the company’s Marketing Headquarters, commented, “Under its Transformation 2020 mid-term business plan, Yokogawa is now exploring new business models such as recurring revenue while also aiming to expand its business in the pharmaceutical and food fields. I am convinced that Sensire’s solutions will accelerate these efforts, and I trust that we will be able to deliver new value to applications where precise temperature control is critical by combining the technologies of both companies.”

JP Asikainen, founder and CEO of Sensire, added, “I believe that this collaboration with Yokogawa will provide us an opportunity to expand the business globally and ensure the transition to the next-generation of cloud architecture. We look forward to making the latest and best cold chain solutions available to customers in a broader range of industries and applications.”

Related links
amnimo Inc .

About Yokogawa
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com .

About Sensire
Sensire Ltd., founded in 2007 by CEO JP Asikainen, offers comprehensive wireless and automatic real-time monitoring products that serve the globally vital climate-controlled chain. The IoT tech company’s solutions help deliver better safety and quality in various cold chain operations from food industry applications to pharmaceutical logistics, as well as in many climate-sensitive healthcare premises. Sensire is committed to being the leading innovator in cold chain IoT technology in order to offer best-in-class products and services to its customers. Headquartered in Joensuu, Finland, the company turnover in FY2018 was EUR 1.5 million. For more information, visit www.sensire.com

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation, Sensire Ltd., or their respective holders.

Contact:

Yokogawa Electric Corporation Philip Lewis Public Relations Manager Email: Yokogawa-pr@cs.jp.yokogawa.com 2-9-32 Nakacho Musashino-shi Tokyo Japan 180-8750 Tel: +81 422-52-5530

Link:

ClickThru

Social Media:

https://www.facebook.com/Yokogawa-127328307136/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release

Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine

Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release

DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI

IQM, a Global Leader for Quantum Computing, to Become the First Listed European Quantum Company, Through Merger with Real Asset Acquisition Corp.23.2.2026 13:49:00 CET | Press release

Global commercial leader with 21 systems sold to 13 customers to date – including 4 out of the top 10 supercomputing centres globally. Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies1), 30+ computers built, own chip factory and quantum data centre. The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and makes IQM the first European quantum company to go public. With the close of this transaction, IQM’s cash position expected to exceed USD 450 million.2 Significant business momentum, with at least USD 35 million3 2025 revenue (unaudited) and over USD 100 million bookings / visibility as of year-end 2025. Strong commercial integrations with high-performance computing and enterprise platforms across the quantum/AI value chain such as NVIDIA, Hewlett Packard Enterprise, AWS, Toyo Corporation and Bechtle AG. Technical successes, achieving greater than 99.9% fidelity for single-qubit and two-

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device23.2.2026 13:30:00 CET | Press release

MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions. MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on

Lenovo Unlocks Data Potential with Next Generation of AI-Driven ThinkEdge Solutions23.2.2026 12:00:00 CET | Press release

New ThinkEdge devices deliver scalable, rugged, and versatile intelligence from gateway to high-performance edge for real-time insights Lenovo™ expanded its ThinkEdge portfolio with a new generation of AI-driven edge computing solutions, including the compact and reliable ThinkEdge SE10n Gen 2, the AI-ready ThinkEdge SE30n Gen 2, the AI-powerhouse ThinkEdge SE60n Gen 2, and Lenovo’s first industrial all-in-one (AIO) Panel PC, the ThinkEdge SE50a. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223166717/en/ ThinkEdge SE10n Gen 2 As enterprises push intelligence closer to operations to improve resilience, reduce latency, and keep sensitive data local, edge computing has become a critical layer between devices, infrastructure, and cloud. Lenovo’s ThinkEdge solutions are purpose-built, industrial-grade edge systems designed to run reliably in harsh, space-constrained environments where traditional servers or PCs are impractic

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye